SynthesisFrontiers in microbiology2026
Global research trends in tuberculosis drug-resistance mechanisms: a bibliometric and cross-database analysis.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge to global tuberculosis control. In 2024, approximately 390,000 individuals developed multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) worldwide, while treatment coverage remained limited to 42%, highlighting persistent gaps in DR-TB management. The mechanisms underlying DR-TB involve resistance-associated mutations, bacterial adaptation, host-pathogen interactions, and drug-target-related processes. A comprehensive evaluation of research trends is needed to clarify the evolution and future directions of this field. Methods: This bibliometric review was conducted with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) 2020 statement. Publications related to DR-TB mechanisms from January 1, 2006, to May 10, 2026, were retrieved from the Web of Science Core Collection (WoSCC), yielding 1,043 eligible records. VOSviewer, CiteSpace, and bibliometric methods were applied to analyze countries/regions, institutions, authors, journals, keywords, and co-citation networks. An independent PubMed dataset ( Results: Annual publications increased markedly after 2015. The dataset included 6,129 authors from 1,581 institutions across 60 countries/regions. The United States was the leading contributor, with the highest number of publications (248) and citations (2,460). Keyword and thematic analyzes revealed that major research areas included drug resistance mechanisms, combination therapy, microbiological analysis, antitubercular agents, and Conclusion: The bibliometric landscape of DR-TB mechanism research has broadened from individual molecular targets to bacterial, host-related, and computational themes. Recent studies show increasing attention to host-directed approaches, molecular modeling, and multidimensional analyzes. These trends may inform future mechanistic and translational research, although their biological and clinical relevance requires independent validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.